| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/13/2023 | 64.67% | Cantor Fitzgerald | → $22 | Reiterates | Neutral → Neutral |
| 08/29/2023 | 64.67% | Cantor Fitzgerald | → $22 | Reiterates | Neutral → Neutral |
| 08/15/2023 | 311.68% | Guggenheim | $56 → $55 | Maintains | Buy |
| 08/11/2023 | 132.04% | Credit Suisse | → $31 | Reiterates | Neutral → Neutral |
| 06/16/2023 | 117.07% | Canaccord Genuity | → $29 | Reiterates | Buy → Buy |
| 05/16/2023 | 161.98% | RBC Capital | → $35 | Reiterates | Outperform → Outperform |
| 04/13/2023 | 117.07% | Canaccord Genuity | → $29 | Initiates Coverage On | → Buy |
| 02/01/2023 | 57.19% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Neutral |
| 12/15/2022 | -2.69% | Goldman Sachs | → $13 | Initiates Coverage On | → Sell |
| 11/08/2022 | 161.98% | RBC Capital | $42 → $35 | Maintains | Outperform |
| 10/06/2022 | 259.28% | Credit Suisse | → $48 | Initiates Coverage On | → Neutral |
| 08/25/2022 | 319.16% | Stifel | $32 → $56 | Upgrades | Hold → Buy |
| 07/18/2022 | 364.07% | BMO Capital | $48 → $62 | Maintains | Outperform |
| 06/17/2022 | 259.28% | BMO Capital | → $48 | Initiates Coverage On | → Outperform |
| 02/18/2022 | 214.37% | RBC Capital | → $42 | Initiates Coverage On | → Outperform |
| 09/24/2021 | 334.13% | Stifel | → $58 | Initiates Coverage On | → Hold |
| 07/12/2021 | 588.62% | William Blair | → $92 | Initiates Coverage On | → Outperform |
| 07/12/2021 | 528.74% | Guggenheim | → $84 | Initiates Coverage On | → Buy |
| 07/12/2021 | 274.25% | JP Morgan | → $50 | Initiates Coverage On | → Neutral |
| 07/12/2021 | — | Jefferies | Initiates Coverage On | → Buy |
What is the target price for Verve Therapeutics (VERV)?
The latest price target for Verve Therapeutics (NASDAQ: VERV) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $22.00 expecting VERV to rise to within 12 months (a possible 64.67% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Verve Therapeutics (VERV)?
The latest analyst rating for Verve Therapeutics (NASDAQ: VERV) was provided by Cantor Fitzgerald, and Verve Therapeutics reiterated their neutral rating.
When is the next analyst rating going to be posted or updated for Verve Therapeutics (VERV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.
Is the Analyst Rating Verve Therapeutics (VERV) correct?
While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a reiterated with a price target of $0.00 to $22.00. The current price Verve Therapeutics (VERV) is trading at is $13.36, which is within the analyst's predicted range.